Overview

Radiation and Chemotherapy With Ipilimumab Followed by Nivolumab for Patients With Stage III Unresectable Non-Small Cell Lung Cancer (NSCLC)

Status:
Active, not recruiting

Trial end date:
2027-03-01

Target enrollment:

Participant gender:

Summary

This study is to determine if Stage III NSCLC patients treated with ipilimumab with thoracic radiation therapy followed by nivolumab monotherapy every 4 weeks for up to 12 months show an improved 12-month Progression Free Survival (PFS) rate compared with a 12-month historical PFS rate of 49% among patients treated in a similar fashion with concurrent chemoradiotherapy.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

H. Lee Moffitt Cancer Center and Research Institute

Treatments:

Antibodies, Monoclonal
Ipilimumab
Nivolumab